M. Miura, S. Onaga, Tetsuhiro Sugiyama, N. Ohama, Yasutaka Miyazato, Takashi Goda, Chiyo Kokubu, Miki Nakamura, Midori Sasada, Masanori Suzuki, Kenichi Honda, Natsuki Hanamura, Kumiko Hamatake, Yuji Akiyama, Yuka Tsutsui, T. Araki, Kazuhiro Ibana, Yoshifumi Niinuma, Yoshiyuki Morishima, Shigeyuki Osada, A. Takita, T. Kimura, H. Yoshida, A. Shintani, T. Seki
fully understood in Japanese patients in real-world clinical practice. To assess medication adherence, this study enrolled 817 NVAF outpatients who took DOAC in 16 hospitals. Hospital pharmacists investigated the medication adherence by pill count and evaluated the patients ʼ knowledge about disease and medication. The percentage of prescribed pills taken was 97.49 ± 6.728 ％ , indicating an excellent medication adherence to DOAC. The proportion of non-adherence patients by definition 1 (percentage of prescribed pills taken < 90 ％ or no visit by the day after reaching the prescription days) was 8.9 ％ and that by definition 2 (definition 1 + did not bring unconsumed drugs) was 19.3 ％ . Regarding the levels of patients ʼ knowledge about disease and medication, approximately 20 ％ of patients had no awareness of NVAF and 30 ％ of patients did not understand the purpose of their medication. Additionally, several factors associated with non-adherence were identified by the multivariate binary logistic regression analysis. A common factor between the non-adherence by definition 1 and definition 2 was the low level of knowledge about medication ． This study demonstrated that Japanese NVAF patients who were taking DOAC had excellent adherence. However, it is suggested that pharmacists strengthen the intervention especially for patients with a low level of medication knowledge, which may lead to further improvement of medication adherence to DOAC.
{"title":"A Multicenter, Large-Scale Real-World Survey on Medication Adherence to Direct Oral Anticoagulants in Patients with Non-Valvular Atrial Fibrillation","authors":"M. Miura, S. Onaga, Tetsuhiro Sugiyama, N. Ohama, Yasutaka Miyazato, Takashi Goda, Chiyo Kokubu, Miki Nakamura, Midori Sasada, Masanori Suzuki, Kenichi Honda, Natsuki Hanamura, Kumiko Hamatake, Yuji Akiyama, Yuka Tsutsui, T. Araki, Kazuhiro Ibana, Yoshifumi Niinuma, Yoshiyuki Morishima, Shigeyuki Osada, A. Takita, T. Kimura, H. Yoshida, A. Shintani, T. Seki","doi":"10.5649/jjphcs.47.132","DOIUrl":"https://doi.org/10.5649/jjphcs.47.132","url":null,"abstract":"fully understood in Japanese patients in real-world clinical practice. To assess medication adherence, this study enrolled 817 NVAF outpatients who took DOAC in 16 hospitals. Hospital pharmacists investigated the medication adherence by pill count and evaluated the patients ʼ knowledge about disease and medication. The percentage of prescribed pills taken was 97.49 ± 6.728 ％ , indicating an excellent medication adherence to DOAC. The proportion of non-adherence patients by definition 1 (percentage of prescribed pills taken < 90 ％ or no visit by the day after reaching the prescription days) was 8.9 ％ and that by definition 2 (definition 1 + did not bring unconsumed drugs) was 19.3 ％ . Regarding the levels of patients ʼ knowledge about disease and medication, approximately 20 ％ of patients had no awareness of NVAF and 30 ％ of patients did not understand the purpose of their medication. Additionally, several factors associated with non-adherence were identified by the multivariate binary logistic regression analysis. A common factor between the non-adherence by definition 1 and definition 2 was the low level of knowledge about medication ． This study demonstrated that Japanese NVAF patients who were taking DOAC had excellent adherence. However, it is suggested that pharmacists strengthen the intervention especially for patients with a low level of medication knowledge, which may lead to further improvement of medication adherence to DOAC.","PeriodicalId":14574,"journal":{"name":"Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84510094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Yamada, Misato Tanabashi, K. Yamasaki, K. Taguchi, F. Hirayama, Hakaru Seo, Junko Morioka
{"title":"Evaluation of Storage Stability of Acetic Acid Ointments as Hospital Preparations","authors":"M. Yamada, Misato Tanabashi, K. Yamasaki, K. Taguchi, F. Hirayama, Hakaru Seo, Junko Morioka","doi":"10.5649/jjphcs.47.171","DOIUrl":"https://doi.org/10.5649/jjphcs.47.171","url":null,"abstract":"","PeriodicalId":14574,"journal":{"name":"Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)","volume":"111 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82465543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ayako Yamaguchi, Yoshiharu Suzuki, Nozomi Taya, Erika Isaka, K. Doki, M. Homma
{"title":"Survey of Description Formats of Medication Notebook","authors":"Ayako Yamaguchi, Yoshiharu Suzuki, Nozomi Taya, Erika Isaka, K. Doki, M. Homma","doi":"10.5649/jjphcs.47.145","DOIUrl":"https://doi.org/10.5649/jjphcs.47.145","url":null,"abstract":"","PeriodicalId":14574,"journal":{"name":"Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77214620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Yamada, M. Go, Mitsuhiro Nishimura, E. Usami, M. Kimura, F. Iwasaki, T. Yoshimura
This study clarifies the utility of guidance on the original nutrition table provided to patients undergoing monotherapy with oral anticancer agents. A satisfaction survey, using a questionnaire, was conducted. Nutritional indicators (weight loss and albumin) and the treatment completion rate were compared for the patients receiving S-1 adjuvant chemotherapy at Ogaki Municipal Hospital before (from February 2017 to February 2018, 68 cases) and after (from March 2018 to August 2019, 37 cases) the creation of the original nutrition table. 83.0 ％ (83/100) of the patients had a high overall satisfaction with the nutrition table, but 27.0 ％ (27/100) wanted to know more about the nutritional ingredients. Although the number of patients with weight loss decreased after the creation of the table (12/37 cases; 32.4 ％ ) compared to before (35/68 cases; 51.5 ％ ), this finding was not significant ( P = 0.07). The treatment completion rates also improved after the creation of the table (30/37, 97.3 ％ ) compared to before (44/68, 64.7 ％ ); however, this was statistically insignificant ( P = 0.12). The satisfaction with the nutrition table prepared this time was high, suggesting that it may lead to the continuation of cancer chemotherapy.
{"title":"Evaluation of the Utility of the Original Nutrition Table for the Patients Undergoing Monotherapy with Oral Anticancer Agents","authors":"S. Yamada, M. Go, Mitsuhiro Nishimura, E. Usami, M. Kimura, F. Iwasaki, T. Yoshimura","doi":"10.5649/jjphcs.47.163","DOIUrl":"https://doi.org/10.5649/jjphcs.47.163","url":null,"abstract":"This study clarifies the utility of guidance on the original nutrition table provided to patients undergoing monotherapy with oral anticancer agents. A satisfaction survey, using a questionnaire, was conducted. Nutritional indicators (weight loss and albumin) and the treatment completion rate were compared for the patients receiving S-1 adjuvant chemotherapy at Ogaki Municipal Hospital before (from February 2017 to February 2018, 68 cases) and after (from March 2018 to August 2019, 37 cases) the creation of the original nutrition table. 83.0 ％ (83/100) of the patients had a high overall satisfaction with the nutrition table, but 27.0 ％ (27/100) wanted to know more about the nutritional ingredients. Although the number of patients with weight loss decreased after the creation of the table (12/37 cases; 32.4 ％ ) compared to before (35/68 cases; 51.5 ％ ), this finding was not significant ( P = 0.07). The treatment completion rates also improved after the creation of the table (30/37, 97.3 ％ ) compared to before (44/68, 64.7 ％ ); however, this was statistically insignificant ( P = 0.12). The satisfaction with the nutrition table prepared this time was high, suggesting that it may lead to the continuation of cancer chemotherapy.","PeriodicalId":14574,"journal":{"name":"Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77266941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shogo Hotta, H. Hida, Masaki Matsubara, Masayuki Miyazaki, Y. Noda, Kiyofumi Yamada
Benzodiazepines (BZDs) are frequently used for insomnia, but the long-term use of BZDs is associated with adverse events such as dependence and withdrawal syndrome. Suvorexant (SUV), an orexin receptor antagonist, is a novel hyp-notic drug that has been shown to be effective for subjective measures of sleep onset and maintenance, safe, and well tolerated in clinical trials. In a long-term clinical trial, SUV discontinuation did not cause rebound insomnia or withdrawal symptoms, suggesting that it may be useful as an alternative drug in long-term users of BZDs. We retrospectively investigated the prescriptions when SUV was introduced to long-term users of BZDs. Sixty patients of long-term users of BZDs, who were prescribed SUV during January 2015 to December 2017, were analyzed. These patients were divided into the add-on group (n = 28) and the switching group (n = 32). The rate of SUV prescription continuation was 92.9 ％ in the add-on group, which was significantly higher ( P = 0.048) than 71.9 ％ in the switching group. The all adverse events rate was 32.1 ％ in the add-on group and 28.1 ％ in the switching group, and there was no significant difference between the two groups. This study revealed that in long-term users of BZDs, add-on and switching were equivalently selected as the method of introducing SUV. It was also suggested that the rate of SUV prescription continuation could be maintained higher in the add-on group than in the switching group.
{"title":"Retrospective Study of Introducing Suvorexant to Long-term Users of Benzodiazepines","authors":"Shogo Hotta, H. Hida, Masaki Matsubara, Masayuki Miyazaki, Y. Noda, Kiyofumi Yamada","doi":"10.5649/jjphcs.47.123","DOIUrl":"https://doi.org/10.5649/jjphcs.47.123","url":null,"abstract":"Benzodiazepines (BZDs) are frequently used for insomnia, but the long-term use of BZDs is associated with adverse events such as dependence and withdrawal syndrome. Suvorexant (SUV), an orexin receptor antagonist, is a novel hyp-notic drug that has been shown to be effective for subjective measures of sleep onset and maintenance, safe, and well tolerated in clinical trials. In a long-term clinical trial, SUV discontinuation did not cause rebound insomnia or withdrawal symptoms, suggesting that it may be useful as an alternative drug in long-term users of BZDs. We retrospectively investigated the prescriptions when SUV was introduced to long-term users of BZDs. Sixty patients of long-term users of BZDs, who were prescribed SUV during January 2015 to December 2017, were analyzed. These patients were divided into the add-on group (n = 28) and the switching group (n = 32). The rate of SUV prescription continuation was 92.9 ％ in the add-on group, which was significantly higher ( P = 0.048) than 71.9 ％ in the switching group. The all adverse events rate was 32.1 ％ in the add-on group and 28.1 ％ in the switching group, and there was no significant difference between the two groups. This study revealed that in long-term users of BZDs, add-on and switching were equivalently selected as the method of introducing SUV. It was also suggested that the rate of SUV prescription continuation could be maintained higher in the add-on group than in the switching group.","PeriodicalId":14574,"journal":{"name":"Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78239137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emi Morimoto, K. Shimizu, M. Takagi, Y. Kondo, Yoshihiro Sakajo, K. Fujita, Y. Itami, H. Momose, Shuya Hirao, K. Nishimura
Cabazitaxel (CBZ), used for castration-resistant prostate cancer, has a high frequency of severe myelosuppression. Pegfilgrastim is administered to prevent febrile neutropenia (FN);however, it may still occur, and in many cases, the CBZ dose is reduced for safety considerations. Therefore, a retrospective survey was conducted to investigate the impact of the initial CBZ dose of 25 mg/m 2 on the myelosuppression status, relative dose intensity (RDI), prostate-specific antigen (PSA) response rate, treatment duration , and overall survival (OS) in Japanese patients. In the 25 mg/m 2 group, 6 patients had neutropenia higher than grade 3 (100 ％ ) and 1 patient had FN. There were 26 patients in the reduced-dose group, and neutropenia of ≥ grade 3 was observed in 5 patients (19 ％ ). The frequency of neutropenia was significantly higher in patients aged ≥ 74 years ( P = 0.017). The 25 mg/m 2 group had significantly higher RDI (median: 96 ％ vs 67 ％ , P = 0.016) and PSA response rate (50 ％ vs 19 ％ , P = 0.043) than the reduced-dose group. In contrast, there was no difference between the two groups in terms of treatment duration (median: 5.9 vs 3.3 months, P = 0.220) and OS (median: 10 vs 13.5 months, P = 0.552). The risk of developing ≥ grade 3 neutropenia was low, and no impact on the OS was observed in the reduced-dose CBZ group. It is recommended to reduce the initial dose of CBZ from 25 mg/m 2 to 20 mg/m 2 in Japanese patients.
卡巴他赛(CBZ)，用于去势抵抗性前列腺癌，有严重骨髓抑制的高频率。Pegfilgrastim用于预防发热性中性粒细胞减少症(FN);然而，它仍然可能发生，并且在许多情况下，出于安全考虑，减少CBZ剂量。因此，本研究对日本患者进行回顾性调查，研究初始CBZ剂量为25mg / m2对骨髓抑制状态、相对剂量强度(RDI)、前列腺特异性抗原(PSA)应答率、治疗持续时间和总生存期(OS)的影响。在25 mg/ m2组中，6例患者中性粒细胞减少高于3级(100%)，1例患者发生FN。减剂量组26例，5例(19%)出现中性粒细胞减少≥3级。年龄≥74岁的患者出现中性粒细胞减少的频率明显较高(P = 0.017)。25 mg/ m2组的RDI(中位数:96% vs 67%， P = 0.016)和PSA反应率(50% vs 19%， P = 0.043)均显著高于低剂量组。相比之下，两组在治疗持续时间(中位数:5.9 vs 3.3个月，P = 0.220)和OS(中位数:10 vs 13.5个月，P = 0.552)方面没有差异。减剂量CBZ组发生≥3级中性粒细胞减少的风险较低，对OS无影响。在日本患者中，建议将CBZ的初始剂量从25mg / m2减少到20mg / m2。
{"title":"Evaluation of the Initial Dose and Therapeutic Effect of Cabazitaxel in Japanese Patients","authors":"Emi Morimoto, K. Shimizu, M. Takagi, Y. Kondo, Yoshihiro Sakajo, K. Fujita, Y. Itami, H. Momose, Shuya Hirao, K. Nishimura","doi":"10.5649/jjphcs.47.150","DOIUrl":"https://doi.org/10.5649/jjphcs.47.150","url":null,"abstract":"Cabazitaxel (CBZ), used for castration-resistant prostate cancer, has a high frequency of severe myelosuppression. Pegfilgrastim is administered to prevent febrile neutropenia (FN);however, it may still occur, and in many cases, the CBZ dose is reduced for safety considerations. Therefore, a retrospective survey was conducted to investigate the impact of the initial CBZ dose of 25 mg/m 2 on the myelosuppression status, relative dose intensity (RDI), prostate-specific antigen (PSA) response rate, treatment duration , and overall survival (OS) in Japanese patients. In the 25 mg/m 2 group, 6 patients had neutropenia higher than grade 3 (100 ％ ) and 1 patient had FN. There were 26 patients in the reduced-dose group, and neutropenia of ≥ grade 3 was observed in 5 patients (19 ％ ). The frequency of neutropenia was significantly higher in patients aged ≥ 74 years ( P = 0.017). The 25 mg/m 2 group had significantly higher RDI (median: 96 ％ vs 67 ％ , P = 0.016) and PSA response rate (50 ％ vs 19 ％ , P = 0.043) than the reduced-dose group. In contrast, there was no difference between the two groups in terms of treatment duration (median: 5.9 vs 3.3 months, P = 0.220) and OS (median: 10 vs 13.5 months, P = 0.552). The risk of developing ≥ grade 3 neutropenia was low, and no impact on the OS was observed in the reduced-dose CBZ group. It is recommended to reduce the initial dose of CBZ from 25 mg/m 2 to 20 mg/m 2 in Japanese patients.","PeriodicalId":14574,"journal":{"name":"Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78893154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ryohei Suzuki, Norikazu Asai, Yuka Oda, Ayumi Nakamura, T. Sakai, Koichi Nagaoka, Kouichi Tanabe, Masaaki Takahashi, F. Ohtsu
{"title":"Pharmaceutical Care in Community-based Integrated Care Wards:","authors":"Ryohei Suzuki, Norikazu Asai, Yuka Oda, Ayumi Nakamura, T. Sakai, Koichi Nagaoka, Kouichi Tanabe, Masaaki Takahashi, F. Ohtsu","doi":"10.5649/jjphcs.47.61","DOIUrl":"https://doi.org/10.5649/jjphcs.47.61","url":null,"abstract":"","PeriodicalId":14574,"journal":{"name":"Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87296160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Toyoda, H. Jinnai, Iori Ueda, Keiichi Matsumoto
Reports of opioid induction with Fentos ® tape (FT) 0.5 mg potency are limited and the appropriate patient-selec-tion-method isn't clear. We report on a retrospective study of the efficacy and safety of opioid induction at FT0.5 mg in our hospital. Patients with cancer who started FT1 mg as a half pasting (0.5 mg potency) during one year from February 2018 to January 2019 and who started FT0.5 mg during one year from February 2019 to January 2020 (Period B) were included in the study. In this study, appropriate cases were defined as those that could be continued for more than 3 days at FT0.5 mg and the number of opioid rescues was < 2 per day. A total of 49 applicable patients in both periods were included, of which 78 ％ (38/49) used FT for opioid induction. In Period B, 30 patients used FT 0.5 mg for opioid induction. Among them, 20 patients were able to continue using the tape for more than 3 days and had opioid rescues < 2 per day. Therefore 67 ％ (20/30) were appropriate cases. The age of appropriate cases was significantly younger (late 70s) than that of inappropriate cases ( P = 0.029). Adverse events occurred in 23 ％ (7/30) of cases, none of which were serious. The induction of opioids in the FT0.5 mg potency was safe with no serious adverse events. However, in terms of efficacy, opioid induction at FT may not be appropriate for patients over 80 years old, and careful patient selection is required.
{"title":"Consideration of Opioid Induction Appropriate Cases for Cancer Pain Using Fentos® Tape 0.5 mg","authors":"M. Toyoda, H. Jinnai, Iori Ueda, Keiichi Matsumoto","doi":"10.5649/jjphcs.47.81","DOIUrl":"https://doi.org/10.5649/jjphcs.47.81","url":null,"abstract":"Reports of opioid induction with Fentos ® tape (FT) 0.5 mg potency are limited and the appropriate patient-selec-tion-method isn't clear. We report on a retrospective study of the efficacy and safety of opioid induction at FT0.5 mg in our hospital. Patients with cancer who started FT1 mg as a half pasting (0.5 mg potency) during one year from February 2018 to January 2019 and who started FT0.5 mg during one year from February 2019 to January 2020 (Period B) were included in the study. In this study, appropriate cases were defined as those that could be continued for more than 3 days at FT0.5 mg and the number of opioid rescues was < 2 per day. A total of 49 applicable patients in both periods were included, of which 78 ％ (38/49) used FT for opioid induction. In Period B, 30 patients used FT 0.5 mg for opioid induction. Among them, 20 patients were able to continue using the tape for more than 3 days and had opioid rescues < 2 per day. Therefore 67 ％ (20/30) were appropriate cases. The age of appropriate cases was significantly younger (late 70s) than that of inappropriate cases ( P = 0.029). Adverse events occurred in 23 ％ (7/30) of cases, none of which were serious. The induction of opioids in the FT0.5 mg potency was safe with no serious adverse events. However, in terms of efficacy, opioid induction at FT may not be appropriate for patients over 80 years old, and careful patient selection is required.","PeriodicalId":14574,"journal":{"name":"Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74340942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kengo Banshoya, Masahiro Okada, F. Murakami, S. Okamoto, Kazuko Okazaki, Hikaru Kimura, Tetsuya Nakamura, Tetsuro Tanaka
Received June 26, 2020 Accepted November 11, 2020 Water intoxication is a group of symptoms that can lead to death. Therefore, it is important to detect the onset of water intoxication at an early stage and to respond promptly and appropriately. The Pharmaceuticals and Medical Devices Agency (PMDA) publishes information reported by the Pharmaceuticals and Medical Devices Safety Information Reporting System. In this study, to contribute to the early detection of the onset of water intoxication, we attempted to detect drugs that can induce water intoxication using PMDA’s database of Japanese Adverse Drug Event Report (JADER). We focused on reports referring to suspected drugs from JADER database of PMDA for about 15 years from April 2004 to March 2019. Adverse drug events were analyzed based on the number of reports. As a result, we detected 34 drugs that are likely to be the causative agents of water intoxication. Among these, “water intoxication” was not stated in 27 drug package inserts. It is important to pay attention to the onset of water intoxication when administering the 27 drugs we detected.
{"title":"Analysis of Water Intoxication by Drugs Using the Japanese Adverse Drug Event Report (JADER) Database","authors":"Kengo Banshoya, Masahiro Okada, F. Murakami, S. Okamoto, Kazuko Okazaki, Hikaru Kimura, Tetsuya Nakamura, Tetsuro Tanaka","doi":"10.5649/jjphcs.47.91","DOIUrl":"https://doi.org/10.5649/jjphcs.47.91","url":null,"abstract":"Received June 26, 2020 Accepted November 11, 2020 Water intoxication is a group of symptoms that can lead to death. Therefore, it is important to detect the onset of water intoxication at an early stage and to respond promptly and appropriately. The Pharmaceuticals and Medical Devices Agency (PMDA) publishes information reported by the Pharmaceuticals and Medical Devices Safety Information Reporting System. In this study, to contribute to the early detection of the onset of water intoxication, we attempted to detect drugs that can induce water intoxication using PMDA’s database of Japanese Adverse Drug Event Report (JADER). We focused on reports referring to suspected drugs from JADER database of PMDA for about 15 years from April 2004 to March 2019. Adverse drug events were analyzed based on the number of reports. As a result, we detected 34 drugs that are likely to be the causative agents of water intoxication. Among these, “water intoxication” was not stated in 27 drug package inserts. It is important to pay attention to the onset of water intoxication when administering the 27 drugs we detected.","PeriodicalId":14574,"journal":{"name":"Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84023819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To cope with the aging population of Japan, medical care needs to be more accessible and efficient. Furthermore, resulting from the measures put in place against COVID-19, the use of information and communication technology (ICT) is expected to be promoted; telemedicine and telepharmacy need to be improved and extended to meet the new demands. To evaluate the implementation of telepharmacy and explore the future agenda, we conducted questionnaire surveys of 5 patients, 5 pharmacists from 4 pharmacies, and 3 physicians who participated in the demonstration project in the National Strategic Special Zone. The survey results confirmed that the quality of medication instruction improved, helping patients to be more relaxed at home; pharmacists were able to check the remaining medicines and medication-storage conditions. Although the introduction of telepharmacy required time and effort from pharmacists, telepharmacy facili-tated making appointments, allowing for advance arrangements for medication shortage, and better preparation of medication instructions. Both patients and physicians rated telepharmacy highly, especially for the reduction in travel time and enabling comfortable, private conversation in the absence of other patients. It is suggested that telepharmacy may be an appropriate complement to in-person medication instruction for patients with stable chronic diseases, and it is expected to play an important role in the future, including supporting measures against COVID-19.
{"title":"Questionnaire Survey of the Telepharmacy Demonstration Project at the National Strategic Special Zone in Yabu City (Hyogo) and Fukuoka City","authors":"Moeno Inukai, Toshiyuki Yokoyama, Rikio Daimon, Nobufumi Matsuura, Ryota Tanaka, Sachiko Hirobe","doi":"10.5649/jjphcs.47.106","DOIUrl":"https://doi.org/10.5649/jjphcs.47.106","url":null,"abstract":"To cope with the aging population of Japan, medical care needs to be more accessible and efficient. Furthermore, resulting from the measures put in place against COVID-19, the use of information and communication technology (ICT) is expected to be promoted; telemedicine and telepharmacy need to be improved and extended to meet the new demands. To evaluate the implementation of telepharmacy and explore the future agenda, we conducted questionnaire surveys of 5 patients, 5 pharmacists from 4 pharmacies, and 3 physicians who participated in the demonstration project in the National Strategic Special Zone. The survey results confirmed that the quality of medication instruction improved, helping patients to be more relaxed at home; pharmacists were able to check the remaining medicines and medication-storage conditions. Although the introduction of telepharmacy required time and effort from pharmacists, telepharmacy facili-tated making appointments, allowing for advance arrangements for medication shortage, and better preparation of medication instructions. Both patients and physicians rated telepharmacy highly, especially for the reduction in travel time and enabling comfortable, private conversation in the absence of other patients. It is suggested that telepharmacy may be an appropriate complement to in-person medication instruction for patients with stable chronic diseases, and it is expected to play an important role in the future, including supporting measures against COVID-19.","PeriodicalId":14574,"journal":{"name":"Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)","volume":"79 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79262964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：